# Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

> **NCT02101580** · PHASE1 · COMPLETED · sponsor: **Polaris Group** · enrollment: 21 (actual)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** ADI-PEG 20

## Key facts

- **NCT ID:** NCT02101580
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-17
- **Primary completion:** 2017-05-05
- **Final completion:** 2017-10-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101580, "Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02101580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*